D
Donald L. Weaver
Researcher at University of Vermont
Publications - 214
Citations - 21231
Donald L. Weaver is an academic researcher from University of Vermont. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 56, co-authored 201 publications receiving 18825 citations. Previous affiliations of Donald L. Weaver include University of Vermont Medical Center.
Papers
More filters
Journal ArticleDOI
The sentinel node in breast cancer--a multicenter validation study.
David N. Krag,Donald L. Weaver,Takamaru Ashikaga,Frederick L. Moffat,V. Suzanne Klimberg,Craig D. Shriver,Sheldon Feldman,Roberto Kusminsky,Michele A. Gadd,Joseph A. Kuhn,Seth P. Harlow,Peter D. Beitsch,Pat Whitworth,Roger S. Foster,Kambiz Dowlatshahi +14 more
TL;DR: Biopsy of sentinel nodes can predict the presence or absence of axillary-node metastases in patients with breast cancer, however, the procedure can be technically challenging, and the success rate varies according to the surgeon and the characteristics of the patient.
Journal ArticleDOI
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Gary H. Lyman,Armando E. Giuliano,Mark R. Somerfield,Al B. Benson,Diane C. Bodurka,Harold J. Burstein,Alistair J. Cochran,Hiram S. Cody,Stephen B. Edge,Sharon Galper,James A. Hayman,Theodore Y. Kim,Cheryl L. Perkins,Donald A. Podoloff,Visa Haran Sivasubramaniam,Roderick R. Turner,Richard L. Wahl,Donald L. Weaver,Antonio C. Wolff,Eric P. Winer +19 more
TL;DR: A review of the available evidence demonstrates that, when performed by experienced clinicians, SNB appears to be a safe and acceptably accurate method for identifying early-stage breast cancer without involvement of the axillary lymph nodes.
Journal ArticleDOI
Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe
TL;DR: A pilot study of breast cancer patients concludes that radiolocalization and selective resection of sentinel lymph nodes is possible; and the sent Sentinel lymph node appears to predict correctly the status of the remaining axilla.
Journal ArticleDOI
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag,Stewart J. Anderson,Thomas B. Julian,Ann M. Brown,Seth P. Harlow,Joseph P. Costantino,Takamaru Ashikaga,Donald L. Weaver,Eleftherios P. Mamounas,Lynne M. Jalovec,Thomas G. Frazier,R. Dirk Noyes,André Robidoux,Hugh M.C. Scarth,Norman Wolmark +14 more
TL;DR: Overall survival, disease-free survival, and regional control were statistically equivalent between groups, and outcome analyses were done in patients who were assessed as having pathologically negative sentinel nodes and for whom follow-up data were available.
Journal ArticleDOI
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
David N. Krag,Stewart J. Anderson,Thomas B. Julian,Ann M. Brown,Seth P. Harlow,Takamaru Ashikaga,Donald L. Weaver,Barbara J Miller,Lynne M. Jalovec,Thomas G. Frazier,R. Dirk Noyes,André Robidoux,Hugh M.C. Scarth,Denise M Mammolito,David R. McCready,Eleftherios P. Mamounas,Joseph P. Costantino,Norman Wolmark +17 more
TL;DR: In the B-32 trial as discussed by the authors, women with invasive breast cancer were randomly assigned to receive either axillary-lymph-node (SLN) resection followed by immediate conventional ALND or SLN resection without ALND if SLNs were negative on intraoperative cytology and histological examination.